Charles River Laboratories International Inc. (CRL): Price and Financial Metrics

Charles River Laboratories International Inc. (CRL): $223.06

1.45 (+0.65%)

POWR Rating

Component Grades








CRL Price/Volume Stats

Current price $223.06 52-week high $275.00
Prev. close $221.61 52-week low $161.65
Day low $218.97 Volume 473,700
Day high $223.18 Avg. volume 561,170
50-day MA $245.40 Dividend yield N/A
200-day MA $218.31 Market Cap 11.49B

CRL Stock Price Chart Interactive Chart >

Charles River Laboratories International Inc. (CRL) Company Bio

Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratorygene therapy and cell therapy services for the PharmaceuticalMedical device and Biotechnology industries. It also supplies assorted biomedical products, outsourcing services, and animals for research and development in the pharmaceutical industry (for example, contract research organization services) and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing. (Source:Wikipedia)

CRL Latest News Stream

Event/Time News Detail
Loading, please wait...

CRL Latest Social Stream

Loading social stream, please wait...

View Full CRL Social Stream

Latest CRL News From Around the Web

Below are the latest news stories about CHARLES RIVER LABORATORIES INTERNATIONAL INC that investors may wish to consider to help them evaluate CRL as an investment opportunity.

What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?

Charles River Laboratories International, Inc. ( NYSE:CRL ) led the NYSE gainers with a relatively large price hike in...

Yahoo | December 27, 2023

Charles River's (CRL) Memphis Site Achieves Crucial Approval

Charles River (CRL) reaches an important milestone in cell therapy manufacturing collaboration with Vertex Pharmaceuticals.

Yahoo | December 19, 2023

Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration

WILMINGTON, Mass. & MEMPHIS, Tenn., December 18, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) today announced an important milestone in their strategic collaboration to manufacture CASGEVY™ (exagamglogene autotemcel [exa-cel]). CASGEVY is approved in some countries for certain eligible patients.

Yahoo | December 18, 2023

Charles River (CRL) Expands 3D In Vitro Services Via New Deal

Charles River (CRL) finalizes agreement with service-based biotechnology company, CELLphenomics.

Yahoo | December 13, 2023

Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening

WILMINGTON, Mass. & BERLIN, December 12, 2023--Charles River expands portfolio of 3D in vitro testing services for oncology research with CELLphenomics' proprietary PD3D tumor model platform.

Yahoo | December 12, 2023

Read More 'CRL' Stories Here

CRL Price Returns

1-mo -1.64%
3-mo -6.65%
6-mo 14.42%
1-year 12.47%
3-year -31.83%
5-year 72.33%
YTD -5.64%
2023 8.49%
2022 -42.17%
2021 50.80%
2020 63.56%
2019 34.97%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!